Stayble Therapeutics AB (STABL) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-0.79x
Stayble Therapeutics AB (STABL) has a Cash Flow-to-Debt Ratio of -0.79x as of December 2025, meaning its operating cash flow of Skr-1.34 Million could theoretically repay -1% of its total liabilities (Skr1.70 Million) in one year. See STABL free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.79x
Operating CF / Total Liabilities
Operating Cash Flow
Skr-1.34 Million
SEK
Total Liabilities
Skr1.70 Million
SEK
Data as of
Dec 2025
Most recent filing
Stayble Therapeutics AB Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Stayble Therapeutics AB across 10 annual periods. For the full cash flow conversion analysis, see Stayble Therapeutics AB (STABL) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Stayble Therapeutics AB (2016–2025)
Year-by-year debt coverage analysis for Stayble Therapeutics AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.96x | Skr-6.72 Million | Skr1.70 Million | ▲ +35.7% |
| 2024 | -6.15x | Skr-14.67 Million | Skr2.38 Million | ▼ -35.8% |
| 2023 | -4.53x | Skr-23.54 Million | Skr5.19 Million | ▲ +29.6% |
| 2022 | -6.44x | Skr-24.89 Million | Skr3.87 Million | ▼ -156.0% |
| 2021 | -2.51x | Skr-9.63 Million | Skr3.83 Million | ▲ +74.3% |
| 2020 | -9.80x | Skr-23.98 Million | Skr2.45 Million | ▼ -33999.6% |
| 2019 | 0.03x | Skr289.39K | Skr10.01 Million | ▲ +101.0% |
| 2018 | -2.87x | Skr-5.42 Million | Skr1.89 Million | ▼ -32.9% |
| 2017 | -2.16x | Skr-2.62 Million | Skr1.21 Million | ▼ -70.5% |
| 2016 | -1.27x | Skr-1.39 Million | Skr1.10 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.